{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-047755","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.214754+00:00","generated_at":"2026-05-24T02:21:21.079992+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Biomea Fusion Q4 net loss $29.3M; cash drops to $58.6M; interim CEO appointed, pivots to diabetes","bullets":["Net loss $29.3M for Q4 2024 ($34.9M in Q4 2023); FY net loss $138.4M vs $117.3M.","Cash reserves $58.6M at Dec 31, 2024, down from $177.2M a year earlier.","Mick Hitchcock appointed interim CEO; all oncology trials terminated, focus shifts to diabetes/obesity.","Icovamenib in severe insulin-deficient T2D: 1.47% HbA1c reduction at Week 26; FDA meeting planned H1 2025.","BMF-650 (oral GLP-1 RA) IND submission planned H2 2025; preclinical appetite suppression data reported."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-047755","json":"https://secwatch.observer/filing/0000950170-25-047755.json","markdown":"https://secwatch.observer/filing/0000950170-25-047755.md","text":"https://secwatch.observer/filing/0000950170-25-047755.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000095017025047755/0000950170-25-047755-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000095017025047755/bmea-20250331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T02:21:21.079992+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}